Nemolizumab Biosimilar - Research Grade

Human

IL-31RA

>1mg/ml

Human IgG2(C130S/R132K/E136G/S137G/C218S/H263Q/R350Q/Q414E/G441DEL/K442DEL)-Kappa

Nolavetbart Biosimilar - Research Grade (ICH5715)

https://www.imgt.org/mAb-DB/

ICH3002

Q8NI17

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of nemolizumab, supplied for research use only and built around the interleukin-31 receptor subunit alpha (IL-31RA) target. It is a human IgG-format antibody that binds IL-31RA and blocks IL-31 engagement of its receptor, reproducing the target specificity of the originator biologic without being the clinical drug; it is not intended for human or veterinary use. The analog is useful as a defined, reproducible reagent for functional and preclinical research: as a blocking tool to interrogate IL-31/IL-31RA signaling, as an isotype-matched or pathway-specific positive control in binding and neutralization assays, as a benchmarking standard when characterizing new anti-IL-31RA candidates, and as a comparator in ADCC or antibody-engineering workflows. It is manufactured to research-grade low-endotoxin specifications (typically less than 1 EU/mg, with ultra-low-endotoxin lots at less than 0.5 EU/mg) suitable for sensitive cell-based work, and is available in bulk milligram-to-gram quantities to support assay development, screening campaigns, and in-vitro model systems. IL-31 receptor subunit alpha (IL-31RA; gene IL31RA, UniProt Q8NI17; also called CRL3/GPL) is a membrane-bound, signal-transducing subunit of the IL-31 receptor complex. It pairs with the oncostatin M receptor beta (OSMR) to form the functional heterodimeric receptor for IL-31, a type 2 cytokine produced largely by Th2 cells. IL-31 binding to IL-31RA/OSMR activates JAK1 and JAK2, driving phosphorylation of STAT1, STAT3, and STAT5B, and also engages the MAPK (ERK1/ERK2) pathway via the adapter SHC1. IL-31RA is expressed on sensory neurons, keratinocytes, and immune cells, positioning it at the neuroimmune interface. This axis is a central driver of pruritus (itch), skin inflammation, epidermal dysregulation, and barrier dysfunction, making IL-31RA a key target in atopic dermatitis and prurigo nodularis research.

IL-31 receptor A, IL-31 receptor subunit alpha, IL-31R subunit alpha, IL-31R-alpha, Cytokine receptor-like 3, Gp130-like monocyte receptor, GLM-R, hGLM-R, Gp130-like receptor, GPL, ZcytoR17, Interleukin-31 receptor subunit alpha, CRL3

Detects human IL-31RA

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Nemolizumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Nemolizumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Nemolizumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Nemolizumab that binds human IL-31RA.